Page 121 - Read Online

Malapelle et al. J Transl Genet Genom 2019;3:3. I https://doi.org/10.20517/jtgg.2018.29 Page 9 of 9

30. Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma
kinase-positive non-small cell lung cancer. Clin Cancer Res 2015;21:2436-9.
31. Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, et al. FDA approval: alectinib for the treatment of metastatic, ALK-positive non-
small cell lung cancer following crizotinib. Clin Cancer Res 2016;22:5171-6.
32. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-
positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 2017;35:2490-8.
33. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, et al. Molecular mechanisms of resistance to first- and second-generation ALK
inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118-33.
34. Costa DB. Resistance to ALK inhibitors: pharmacokinetics, mutations or bypass signaling? Cell Cycle 2017;16:19-20.
35. Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-
acquired resistance. Acta Pharm Sin B 2015;5:34-7.
36. Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol 2018;25:S59-67.
37. Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci 2018;109:572-80.
38. Lin JJ, Riely GJ, Shaw AT, et al. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 2017;7:137-55.
39. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, et al. Molecular mechanisms of resistance to first- and second-generation ALK
inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118-33.
40. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an
international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017;18:1590-9.